Novartis AG, incorporated on February 29, 1996, provides healthcare solutions. The Company is a mult...

1. Novartis AG (NVS) Company Profile
Novartis AG, incorporated on February 29, 1996, provides healthcare solutions. The Company is a
multinational group of companies specializing in the research, development, manufacturing and
marketing of a range of healthcare products led by pharmaceuticals. Its portfolio includes
medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools,
over-the-counter and animal health products. The Company has five segments: Pharmaceuticals,
which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic
pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals; vaccines
and diagnostics, which include human vaccines and blood-testing diagnostics, and consumer health,
which include over-the-counter medicines (OTC) and Animal Health. On April 8, 2011, the Company
acquired the remaining non-controlling interest in Alcon, Inc. In December 2013, Alliance Pharma
plc announced that its wholly owned subsidiary, Alliance Pharmaceuticals Limited, acquired all the
United Kingdom and Republic of Ireland (ROI) rights to Lypsyl from Novartis AG.
In April 2011, Novartis sells global rights to Elidel, a medicine to treat atopic dermatitis to Meda. In
March 2011, Novartis completes acquisition of majority stake in Zhejiang Tianyuan vaccines
company in China. In March 2011, the Company acquired Genoptix, Inc. In October 2011, Novartis
discontinues development of AGO178 for depressive disorder. In December 2011, the Company
discontinues development of PRT128 for acute coronary syndrome and chronic coronary heart
disease, and SMC021 for osteoporosis and osteoarthritis. In April 2011, Alcon's portfolio of generic
ophthalmic medicines sold through its Falcon business unit primarily in the United States.
Pharmaceuticals Division
The Company's Pharmaceuticals Division researches, develops, manufactures, distributes and sells
patented prescription medicines in the therapeutic areas, such as Oncology; Primary Care,
consisting of Primary Care medicines and Established Medicines, and Specialty Care, consisting of
Ophthalmology, Neuroscience, Integrated Hospital Care, and Critical Care medicines. The
Pharmaceuticals Division is organized into global business franchises responsible for the
commercialization of various products, as well as Novartis Oncology, a business unit responsible for
the global development and commercialization of oncology products, and Novartis Molecular
Diagnostics, a business responsible for the development and commercialization of diagnostic tests
and services related to its pharmaceuticals portfolio and therapeutic areas.
The Company's Oncology products include Afinitor/Votubia, Exjade, Sandostatin SC/Sandostatin LAR
, Femara , Zometa, Tasigna and Gleevec/Glivec. Gleevec/Glivec, which is a signal transduction
inhibitor approved to treat patients with certain forms of chronic myeloid leukemia (CML) and
gastrointestinal stromal tumors (GIST). Tasigna is a signal transduction inhibitor of the tyrosine
kinase activity of Bcr-Abl, KIT+ and the PDGF-receptor. Zometa is a treatment to reduce or delay
skeletal-related events (SREs), including pathologic fracture, spinal cord compression, and/or
requirement of radiation therapy or surgery to bone, in patients with bone metastases (cancer that
has spread to the bones) from solid tumors and multiple myeloma. Femara is a once-daily oral
aromatase inhibitor for the treatment of early stage or advanced breast cancer in postmenopausal
women. Sandostatin SC/Sandostatin LAR is indicated for the treatment of patients with acromegaly,
a chronic disease caused by over-secretion of pituitary growth hormone in adults. Sandostatin is also
indicated for the treatment of patients with certain symptoms associated with carcinoid tumors and

2. other types of gastrointestinal and pancreatic neuroendocrine tumors. Exjade is an oral iron chelator
approved for the treatment of chronic iron overload due to blood transfusions in patients over two
years of age who have a range of underlying anemias. Patients with congenital and acquired chronic
anemia, such as thalassemia, sickle cell disease and myelodysplastic syndromes, require
transfusions, which puts them at risk of iron overload. Afinitor/Votubia is an oral inhibitor of the
mTOR pathway.
The Company's Primary Care products include Arcapta Neohaler/Onbrez Breezhaler, Diovan,
Exforge, Tekturna/Rasilez, Galvus, Reclast/Aclasta, Voltaren/Cataflam, Ritalin, Ritalin LA, Focalin
and Focalin XR. Its Specialty Care products include Lucentis, Gilenya, Exelon, Extavia and Comtan,
and Stalevo. Its Integrated Hospital Care include Zortress/Certican, Ilaris, Neoral and Myfortic.The
Company's Critical Care products include Xolair and Tobi Podhaler. As of December 31, 2011, the
products under development includes ACZ885, which is being investigated for the secondary
prevention of cardiovascular events and for the treatment of Diabetes Mellitus; AEB071
(sotrastaurin) is a low molecular weight, selective inhibitor of protein kinase-C (PKC); AFQ056
(mavoglurant) is a metabotropic glutamate receptor 5 (mGluR5) antagonist in Phase II development
for the treatment of Parkinson's disease levodopa-induced dyskinesia; AIN457 (secukinumab) is a
human monoclonal antibody neutralizing interleukin-17A, a key pro-inflammatory cytokine expressed
by TH17 cells and other types of white blood cells; BAF312 is an oral, second-generation sphingosine
1-phosphate receptor modulator in Phase II development for relapsing-remitting multiple sclerosis;
DEB025 (alisporivir) is a cyclophilin inhibitor for the treatment of Hepatitis C virus infection (HCV);
Gileny a line treatment for relapsing forms of MS; Exjade (deferasirox) is an oral iron chelator in
development for use in patients with non-transfusion-dependent thalassemia (NTDT); INC424
(ruxolitinib) is an investigational Janus kinase (JAK) inhibitor, and Zortress/Certican (everolimus) is
an mTOR inhibitor with immune/non-immune cell proliferation inhibition being developed for
prevention of solid organ transplant rejection.
Alcon Division
The Company's Alcon Division discovers, develops, manufactures, distributes and sells eye care
products. Alcon is engaged in eye care with product offerings in Surgical, Ophthalmic
Pharmaceuticals and Vision Care. In Surgical, Alcon develops, manufactures, distributes and sells
ophthalmic surgical equipment, instruments, disposable products and intraocular lenses. In
Pharmaceutical, Alcon discovers, develops, manufactures, distributes and sells medicines to treat
chronic and acute diseases of the eye, as well as over-the-counter medicines for the eye. In Vision
Care, Alcon develops, manufactures, distributes and sells contact lenses and lens care products.
Alcon's Surgical portfolio includes the Infiniti vision system for cataract procedures, the
Constellation vision system for retinal operations, and the AcrySof family of intraocular lenses
(IOLs), including the AcrySof IQ, AcrySof IQ ReSTOR, AcrySof IQ Toric and AcrySof IQ ReSTOR
Toric IOLs. During the year ended December 31, 2011, its Alcon Division launched the LenSx
femtosecond laser, a technology in cataract surgery, which increases the precision and
reproductibility for corneal incisions, capsulorhexis and lens fragmentation steps of the procedure.
In addition, Alcon provides advanced viscoelastics, surgical solutions, surgical packs and other
disposable products for cataract and vitreoretinal surgery.
Alcon Division's Ophthalmic Pharmaceuticals business combines Alcon's range of pharmaceuticals
with selected ophthalmic products (excluding Lucentis) previously marketed by the Novartis
Pharmaceuticals Division. The products treat chronic and acute diseases of the eye including
glaucoma and allergies, as well as anti-infective/anti-inflammatory and dry eye treatments. our Alcon
Division's Ophthalmic Pharmaceuticals portfolio include Travatan Z solution and DuoTrav solution

3. for the treatment of elevated intraocular pressure associated with glaucoma; Vigamox solution for
bacterial conjunctivitis; Pataday solution for ocular itching associated with allergic conjunctivitis;
and Nevanac suspension for eye inflammation following cataract surgery. Alcon launched a number
of products during 2011, including Dailies Total 1 lenses, Opti-Free EverMoist Multi Purpose
Disinfecting Solution, LenSx laser, AcrySof IQ ReSTOR Toric lens, AcrySof IQ Toric T6-T9 lens,
Travatan BAK-free solution, DuoTrav BAK-free solution, Moxeza solution and Systane Balance eye
drops.
Sandoz Division
The Company's Sandoz Division is a global generic pharmaceuticals company that develops,
manufactures, distributes and sells prescription medicines, as well as pharmaceutical and
biotechnological active substances, which are not protected by valid and enforceable third-party
patents. The Sandoz Division has activities in Retail Generics, Anti-Infectives, and
Biopharmaceuticals and Oncology Injectables. In Retail Generics, Sandoz develops, manufactures
and markets active ingredients and finished dosage forms of pharmaceuticals, as well as supplying
active ingredients to third parties. In Anti-Infectives, Sandoz develops and manufactures active
pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by retail generics
and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and
markets protein- or other biotechnology-based products (biosimilars or follow-on biologics) and sells
biotech manufacturing services to other companies.
In Oncology Injectables, Sandoz develops, manufactures and markets primarily cytotoxic products
for the hospital market. During 2011, the Company launched generic docetaxel (Taxotere), higher-
strength generic amlodipine-benazepril (Lotrel), generic meropenem (Merem) injection, and the
formation of a women's health portfolio with generic Seasonale, Nordette, Yaz and Yasmin. The
product launched in various European countries included generic docetaxel, generic anastrazole
(Arimidex), and valsartan/covalsartan (an early entry generic version of Novartis Pharmaceuticals'
Diovan/Co-Diovan).
Vaccines and Diagnostics Division
The Company's Vaccines and Diagnostics Division researches, develops, manufactures, distributes
and sells preventive vaccines and diagnostic tools. Novartis Vaccines is a global developer and
manufacturer of human vaccines. Novartis Diagnostics is a blood testing and molecular diagnostics
business dedicated to preventing the spread of infectious diseases through blood-screening tools
that protect the world's blood supply. Novartis Vaccines' products include influenza, meningococcal,
pediatric, adult and travel vaccines.
The Company's influenza vaccines include Agrippal, Fluad, Fluvirin and Optaflu. Its Meningococcal
Vaccines includes Menjugate and Menveo. Its travel vaccines include Encepur Children, Encepur
Adults, Ixiaro and Rabipur/Rabavert. Its Pediatric Vaccines include Polioral and Quinvaxem.
Consumer Health
Consumer Health consists of two Divisions: OTC (over-the-counter medicines) and Animal Health.
Each has its own research, development, manufacturing, distribution and selling capabilities. OTC
offers readily available consumer medicine. Animal Health provides veterinary products for farm and
companion animals.
OTC (over-the-counter medicines) offers products for the treatment and prevention of common

4. medical conditions and ailments. OTC business focuses on a group of global brands in product
categories that include treatments for cough/cold/respiratory (Triaminic, Otrivin,
TheraFlu/NeoCitran), pain relief (Excedrin, Voltaren), digestive health (Benefiber, Prevacid24HR,
Pantoloc Control), dermatology (Lamisil, Fenistil), and smoking cessation (Habitrol/Nicotinell).
Animal Health offers products and services focusing on both companion and farm animals (including
cultivated fish). Key products for companion animals include Atopica (atopic dermatitis
management), Deramaxx and Onsior (pain relief), Fortekor (heart failure in dogs, chronic renal
insufficiency in cats), and Sentinel/Milbemax/Interceptor (intestinal parasite control and heartworm
prevention), while farm animal products include the therapeutic anti-infective Denagard, an
antimicrobial used to treat and control bacteria in swine, CLiK, an insect growth regulator used to
control blowfly strike in sheep, cattle vaccines used to prevent respiratory and reproductive diseases
in beef and dairy cattle, and Zolvix, a sheep drench representing the new sheep anthelmintic class.
Aquaculture products include vaccines and treatments mainly used in salmon farming.
http://www.reuters.com/finance/stocks/companyProfile?symbol=NVS